E-GEOD-15325
Ontology highlight
ABSTRACT:
PROVIDER: E-GEOD-15325 | ExpressionAtlas | 2014-07-03
REPOSITORIES: ExpressionAtlas
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| E-GEOD-15325-analysis-methods.tsv | Tabular | |||
| E-GEOD-15325-atlasExperimentSummary.Rdata | Rdata | |||
| E-GEOD-15325-configuration.xml | Xml | |||
| E-GEOD-15325-percentile-ranks.tsv | Tabular | |||
| E-GEOD-15325-zoomifications-log.tsv | Tabular |
Items per page: 5 1 - 5 of 100 |
Similar Datasets
Project description:K-ras is one of the most frequently mutated human oncogenes. Activation of K-ras can lead to either senescence or proliferation in primary cells. The precise mechanism governing these distinct outcomes remains unclear. Here we utilized a loss-of-function screen to assess the role of specific genes identified as potential key regulators of K-ras driven oncogenesis. Using this approach, we identify the transcription factor Wt1 as an inhibitor of senescence in primary cells expressing oncogenic K-ras. Deletion or suppression of Wt1 expression leads to senescence of primary cells expressing oncogenic K-ras under the control of the native promotor at physiological levels, but has no effect on cells expressing wild-type K-ras. Wt1 contributes to K-ras driven lung tumorigenesis in vivo and loss of Wt1 is specifically deleterious to human lung cancer cell lines that are dependent on oncogenic K-ras. Taken together, these observations reveal a novel role for Wt1 as a key regulator of the complex genetic network required for the oncogenic effect of the small GTPase K-ras. We compare the expression profiles of Wild type, K-ras mutant, Wt1-null, and double K-ras mutant/Wt1-null mouse embryonic fibroblasts (MEFs). The study provides insights into the transcriptional role of Wt1 in the context of oncogenic K-ras.
2010-03-01 | GSE15325 | GEO
Project description:K-ras is one of the most frequently mutated human oncogenes. Activation of K-ras can lead to either senescence or proliferation in primary cells. The precise mechanism governing these distinct outcomes remains unclear. Here we utilized a loss-of-function screen to assess the role of specific genes identified as potential key regulators of K-ras driven oncogenesis. Using this approach, we identify the transcription factor Wt1 as an inhibitor of senescence in primary cells expressing oncogenic K-ras. Deletion or suppression of Wt1 expression leads to senescence of primary cells expressing oncogenic K-ras under the control of the native promotor at physiological levels, but has no effect on cells expressing wild-type K-ras. Wt1 contributes to K-ras driven lung tumorigenesis in vivo and loss of Wt1 is specifically deleterious to human lung cancer cell lines that are dependent on oncogenic K-ras. Taken together, these observations reveal a novel role for Wt1 as a key regulator of the complex genetic network required for the oncogenic effect of the small GTPase K-ras. We compare the expression profiles of Wild type, K-ras mutant, Wt1-null, and double K-ras mutant/Wt1-null mouse embryonic fibroblasts (MEFs). The study provides insights into the transcriptional role of Wt1 in the context of oncogenic K-ras. MEFs were infected with adenoviral Cre to activate K-ras (6 samples), knockout Wt1 (5 samples), both activate K-ras and knockout Wt1 (7 samples). As a control, MEFs were infected with adenoviral GFP (5 samples). RNA was isolated using Trizol 7 days after infection. RNA was further prepared by passage over an RNeasy column. cDNA synthesis, biotinylation of cRNA and hybridization to mouse Genechip 430A v2 containing 39,000 probes was performed according to the manufacturer's instructions (Affymetrix, Santa Clara). Microarray data was normalized with Expression Console software (Affymetrix, Santa Clara) using RMA algorithms.
2010-03-06 | E-GEOD-15325 | biostudies-arrayexpress
Project description:Transcription profiling by array of mouse embryonic fibroblasts expressing CBX8 or BMI1
2014-07-03 | E-MEXP-793 | ExpressionAtlas
Project description:Transcriptional profiling by array of mouse wild-type and Insulin receptor (InsR)/Igf1 receptor (Igf1R) double knockout mutant Sertoli cells from testis at embryonic day E17.5 and Postnatal day 5
2015-11-02 | E-MTAB-1192 | ExpressionAtlas
Project description:Transcription profiling by array of mouse fibroblasts mutant for Oct-1 after gamma irradiation
2014-08-15 | E-GEOD-2084 | ExpressionAtlas
Project description:Transcription profiling by array of mouse embryonic fibroblasts from p27 -/- knockouts and wild-type controls to study the role of p27 in regulating the cell cycle
2014-07-25 | E-MTAB-2790 | ExpressionAtlas
Project description:Expression data of mouse hematopoietic cells, Nr4a1/3 wild type and double mutant
2014-10-27 | E-GEOD-31042 | ExpressionAtlas
Project description:Molecular profiling of Ctcf hemizygous mouse embryonic fibroblasts: RNA-seq
2018-09-17 | E-MTAB-6259 | ExpressionAtlas
Project description:Transcription profiling of mouse wild type and Lim1-null renal vesicles microdissected from embryonic day 12.5 kidneys
2014-07-08 | E-GEOD-7257 | ExpressionAtlas
Project description:<p>Although multi-agent combination chemotherapy is curative in a significant fraction of childhood acute lymphoblastic leukemia (ALL) patients, 20% of cases relapse and most die due to chemo-refractory disease. Here we used whole-exome and whole-genome sequencing to analyze the mutational landscape and pattern of clonal evolution at relapse in pediatric ALL cases. These analyses showed that ALL relapses originate from a common ancestral precursor clone of the diagnosis and relapsed populations and frequently harbor mutations implicated in chemotherapy resistance. RAS-MAPK pathway activating mutations in NRAS, KRAS and PTPN11 were present in 24/55 (44%) cases in our series. Notably, while some cases showed emergence of RAS mutant clones at relapse, in others, RAS mutant clones present at diagnosis were replaced by RAS wild type populations. Mechanistically, functional dissection of mouse and human wild type Kras and mutant Kras (Kras G12D) isogenic leukemia cells demonstrated induction of methotrexate resistance, but also improved response to vincristine, in mutant Kras- expressing lymphoblasts. These results identify chemotherapy driven selection as a central mechanism of leukemia clonal evolution and pave the road for the development of tailored personalized therapies for the treatment of relapsed ALL. </p>
| phs001072 | dbGaP